PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
 
Ann Rheum Dis. May 2005; 64(5): 765–766.
Published online Sep 30, 2004. doi:  10.1136/ard.2004.026534
PMCID: PMC1755470
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis
D Kiortsis, A Mavridis, S Vasakos, S Nikas, and A Drosos
Laboratory of Physiology, Medical School, University of Ioannina, 45110 Ioannina, Greece.
Abstract
Objective: To assess the effects of infliximab infusions on insulin sensitivity in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
Methods: 45 patients (28 with RA, 17 with AS) aged 19–74 years were studied. All patients were treated with intravenous infliximab. A complete biochemical profile was obtained before and after 6 months' treatment with infliximab. The Homoeostasis Model Assessment (HOMA) Index was used to measure insulin resistance and the Quantitative Insulin Sensitivity Check Index (QUICKI) to measure insulin sensitivity.
Results: In the whole study group, no significant changes of the HOMA Index or QUICKI were seen. In the tertile of patients with the highest insulin resistance, a significant decrease of the HOMA Index and increase of the QUICKI was found (p<0.01 for both).
Conclusions: The results suggest that infliximab treatment may have beneficial effects on insulin sensitivity in the most insulin resistant patients with RA and AS.
Articles from Annals of the Rheumatic Diseases are provided here courtesy of
BMJ Group